MedPath

Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients

Completed
Conditions
Polycythemia Vera
Essential Thrombocythemia
Registration Number
NCT02893410
Lead Sponsor
University Hospital, Brest
Brief Summary

Patients treated with oral or sub-cutaneous drugs for polycythemia vera or essential thrombocythemia completed an unique paper questionnaire in order to describe their observance, the side effects and their own appreciation of the taken drug.

Detailed Description

During one year, all patients with PV or ET followed in our centre, and who took a drug to treat their MPN, were identified.

The investigators submitted by mail or directly at the consultation a unique questionnaire containing 25 questions concerning patients characteristics, evaluation of observance, identification of side effects and own appreciation of the drug.

After completion of the questionnaire, the patients were identified and followed to collect new data about thrombotic events or phenotypic evolution.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
286
Inclusion Criteria
  • Patients with PV or ET or SMF
  • Patients who took oral or sub-cutaneous drugs to treat their MPN.
  • Patients who agreed to complete the questionnaire
Exclusion Criteria
  • Patients with low risk PV or ET who do not take treatment
  • Patients unable to complete the questionnaire

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Rate of adherence to drug prescriptionAt inclusion

prospective evaluation in a one shot questionnaire given to each treated patient seen at the consultation distributed between december 2014 and december 2015

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHRU de Brest

🇫🇷

Brest, France

© Copyright 2025. All Rights Reserved by MedPath